GSK Poised for Pfizer Battle in RSV Vaccine Market

  • 📰 WSJhealth
  • ⏱ Reading Time:
  • 19 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 53%

Brasil Notícia Notícia

Brasil Últimas Notícias,Brasil Manchetes

GSK said its experimental vaccine against respiratory syncytial virus sharply reduced the risk of disease in a key trial

LONDON– GSK PLC said its experimental vaccine against respiratory syncytial virus sharply reduced the risk of disease in a key trial, paving the way for a contest with Pfizer Inc.

in what the companiesRespiratory syncytial virus, or RSV, is a common virus that proves deadly for some 14,000 older adults in the U.S. every year. Although identified decades ago, there are no approved vaccines against the virus, which in most people causes cold-like symptoms but can lead to more severe disease affecting the lungs in young babies and older adults.

 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.

Which methodology did they use?

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 413. in BR

Brasil Últimas Notícias, Brasil Manchetes